Clinical Trials

NCT Number: NCT04989946 Phase: Phase 1|Phase 2 Trial Summary: The current protocol will examine the use of a plasmid DNA vaccine encoding AR, alone or with nivolumab, to induce and/or augment therapeutic T-cells following androgen deprivation – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Wisconsin, Madison Acronym:

NCT Number: NCT04656678 Phase: Not Applicable Trial Summary: The purpose of this research study is to determine the safety and feasibility of using the UroNav software and DynaCAD software for planning and treating prostate cancer as an add – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Northwell Health Acronym:

NCT Number: NCT05454488 Phase: Phase 2 Trial Summary: To learn if using cryotherapy to treat only the part of the prostate known to contain cancer is effective in controlling pros – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): M.D. Anderson Cancer Center Acronym:

NCT Number: NCT04402151 Phase: Phase 2 Trial Summary: This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym: PSMA SBRT-SIB

NCT Number: NCT04485767 Phase: Not Applicable Trial Summary: The overall goal of this study is to determine if implementing structured exercises prevent decline in muscle mass, muscle strength and physical function in men with prostate cance – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Dana-Farber Cancer Institute Acronym:

NCT Number: NCT05489211 Phase: Phase 2 Trial Summary: TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): AstraZeneca Acronym:

NCT Number: NCT05558956 Phase: Early Phase 1 Trial Summary: Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning pro – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): BAMF Health Acronym:

NCT Number: NCT05932862 Phase: PHASE1 Trial Summary: This is a first-in-human, multicenter, open-label Phase I study. The study will be comprised of a dose escalation part followed by a dose selection optimization part. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Exelixis Acronym:

NCT Number: NCT05617040 Phase: Phase 1|Phase 2 Trial Summary: This is a multi-centre, Phase 1/2, open-label clinical trial of the VTP-850 prime-boost immunotherapeutic in men with biochemical recurrence after definitive local therapy for pros – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Barinthus Biotherapeutics Acronym:

NCT Number: NCT04787744 Phase: Phase 2|Phase 3 Trial Summary: The primary goal of this study is to determine if adding PET-directed local therapy improves disease control compared to standard systemic therapy alone in Veterans with oligorecur – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): VA Office of Research and Development Acronym: VA STARPORT